A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn’s disease showed clinical improvement at high serum levels. - Yacyshyn,B.R.; Chey,W.Y.; Goff,J. (Gastroenterology, 2001)